The interaction of the neuroprotective compounds riluzole and phenobarbital with AMPA-type glutamate receptors: A patch-clamp study

Pharmacology

Volumn 85, Issue 1, 2010, Pages 54-62

  Jin, Ling Jing ^a,b   Schlesinger, Friedrich ^a   Song, Yun Ping ^a   Dengler, Reinhard ^a   Krampfl, Klaus ^a  

^a CENTER FOR SYSTEMS NEUROSCIENCE   (Germany)

^b TONGJI HOSPITAL OF TONGJI UNIVERSITY   (China)

Author keywords

Amino 3 hydroxy 5 methyl 4 isoxazole propionic acid antagonist; Patch clamp technique; Phenobarbital; Riluzole

Indexed keywords

AMPA RECEPTOR; GLUTAMATE RECEPTOR; PHENOBARBITAL; RILUZOLE;

AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; HUMAN; HUMAN CELL; NEUROPROTECTION; PATCH CLAMP; PRIORITY JOURNAL;

AREA UNDER CURVE; CELL LINE; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; NEUROPROTECTIVE AGENTS; PATCH-CLAMP TECHNIQUES; PHENOBARBITAL; RECEPTORS, AMPA; RILUZOLE;

EID: 73249149097     PISSN: 00317012     EISSN: None     Source Type: Journal    
DOI: 10.1159/000268641     Document Type: Article

References (37)

1. Dingledine R, Borges K, Bowie D, Traynelis SF: The glutamate receptor ion channels. Pharmacol Rev 1999; 51: 7-61.
2. Van den Bosch L, Robberecht W: Different receptors mediate motor neuron death induced by short and long exposures to excitotoxicity. Brain Res Bull 2000; 53: 383-388.
3. Carriedo SG, Yin HZ, Weiss JH: Motor neurons are selectively vulnerable to AMPA/ kainate receptor-mediated injury in vitro. J Neurosci 1996; 16: 4069-4079.
4. Ikonomidou C, Qin Qin Y, Labruyere J, Olney JW: Motor neuron degeneration induced by excitotoxin agonists has features in common with those seen in the SOD-1 transgenic mouse model of amyotrophic lateral sclerosis. J Neuropathol Exp Neurol 1996; 55: 211-224.
5. Saroff D, Delfs J, Kuznetsov D, Geula C: Selective vulnerability of spinal cord motor neurons to non-NMDA toxicity. Neuroreport 2000; 11: 1117-1121.
6. 2+-permeable AMPA receptors and selective vulnerability of motor neurons. J Neurol Sci 2000; 180: 29-34.
7. 2+ influx and not via calpain inhibition. Neuropharmacology 2002; 42: 706-713.
8. Van Damme P, Dewil M, Robberecht W, Van den Bosch L: Excitotoxicity and amyotrophic lateral sclerosis. Neurodegener Dis 2005; 2: 147-159.
9. Bensimon G, Lacomblez L, Meininger V: A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group. N Engl J Med 1994; 330: 585-591.
10. Doble A: The pharmacology and mechanism of action of riluzole. Neurology 1996; 47: S233-S241.
11. Albo F, Pieri M, Zona C: Modulation of AMPA receptors in spinal motor neurons by the neuroprotective agent riluzole. J Neurosci Res 2004; 78: 200-207.
12. Zona C, Cavalcanti S, De Sarro G, Siniscalchi A, Marchetti C, Gaetti C, Costa N, Mercuri N, Bernardi G: Kainate-induced currents in rat cortical neurons in culture are modulated by riluzole. Synapse 2002; 43: 244-251.
13. Kamiya Y, Andoh T, Furuya R, Hattori S, Watanabe I, Sasaki T, Ito H, Okumura F: Comparison of the effects of convulsant and depressant barbiturate stereoisomers on AMPA-type glutamate receptors. Anesthesiology 1999; 90: 1704-1713.
14. Brown-Croyts LM, Caton PW, Radecki DT, McPherson SL: Phenobarbital pre-treatment prevents kainic acid-induced impairments in acquisition learning. Life Sci 2000; 67: 643-650.
15. Schlesinger F, Tammena D, Krampfl K, Bufler J: Two mechanisms of action of the adamantane derivative IEM-1460 at human AMPA-type glutamate receptors. Br J Pharmacol 2005; 145: 656-663.
16. Krampfl K, Schlesinger F, Cordes AL, Bufler J: Molecular analysis of the interaction of the pyrazine derivatives RPR119990 and RPR117824 with human AMPA-type glutamate receptor channels. Neuropharmacology 2006; 50: 479-490.
17. Mansour M, Nagarajan N, Nehring RB, Clements JD, Rosenmund C: Heteromeric AMPA receptors assemble with a preferred subunit stoichiometry and spatial arrangement. Neuron 2001; 32: 841-853.
18. Hamill OP, Marty A, Neher E, Sakmann B, Sigworth FJ: Improved patch-clamp techniques for high-resolution current recording from cells and cell-free membrane patches. Pflugers Arch 1981; 391: 85-100.
19. Franke C, Hatt H, Dudel J: Liquid filament switch for ultra-fast exchanges of solutions at excised patches of synaptic membrane of crayfish muscle. Neurosci Lett 1987; 77: 199-204.
20. Heckmann M, Bufler J, Franke C, Dudel J: Kinetics of homomeric GluR6 glutamate receptor channels. Biophys J 1996; 71: 1743-1750.
21. Jahn K, Bufler J, Franke C: Kinetics of AMPA-type glutamate receptor channels in rat caudate-putamen neurones show a wide range of desensitization but distinct recovery characteristics. Eur J Neurosci 1998; 10: 664-672.
22. Krampfl K, Schlesinger F, Zorner A, Kappler M, Dengler R, Bufler J: Control of kinetic properties of GluR2 flop AMPA-type channels: impact of R/G nuclear editing. Eur J Neurosci 2002; 15: 51-62.
23. Bufler J, Wilhelm R, Parnas H, Franke C, Dudel J: Open channel and competitive block of the embryonic form of the nicotinic receptor of mouse myotubes by (+)-tubocurarine. J Physiol 1996; 495: 83-95.
24. Debono MW, Le Guern J, Canton T, Doble A, Pradier L: Inhibition by riluzole of electrophysiological responses mediated by rat kainate and NMDA receptors expressed in Xenopus oocytes. Eur J Pharmacol 1993; 235: 283-289.
25. Centonze D, Calabresi P, Pisani A, Marinelli S, Marfia GA, Bernardi G: Electrophysiology of the neuroprotective agent riluzole on striatal spiny neurons. Neuropharmacology 1998; 37: 1063-1070.
26. Urbani A, Belluzzi O: Riluzole inhibits the persistent sodium current in mammalian CNS neurons. Eur J Neurosci 2000; 12: 3567-3574.
27. Xu L, Enyeart JA, Enyeart JJ: Neuroprotective agent riluzole dramatically slows inactivation of Kv1.4 potassium channels by a voltage-dependent oxidative mechanism. J Pharmacol Exp Ther 2001; 299: 227-237.
28. Cao YJ, Dreixler JC, Couey JJ, Houamed KM: Modulation of recombinant and native neuronal SK channels by the neuroprotective drug riluzole. Eur J Pharmacol 2002; 449: 47-54.
29. Mohammadi B, Krampfl K, Moschref H, Dengler R, Bufler J: Interaction of the neuroprotective drug riluzole with GABA A and glycine receptor channels. Eur J Pharmacol 2001; 415: 135-140.
30. He Y, Benz A, Fu T, Wang M, Covey DF, Zorumski CF, Mennerick S: Neuroprotective agent riluzole potentiates postsynaptic GABA A receptor function. Neuropharmacology 2002; 42: 199-209.
31. Jahn K, Schlesinger F, Jin LJ, Dengler R, Bufler J, Krampfl K: Molecular mechanisms of interaction between the neuroprotective substance riluzole and GABA A-receptors. Naunyn Schmiedebergs Arch Pharmacol 2008; 378: 53-63.
32. Marszalec W, Narahashi T: Use-dependent pentobarbital block of kainate and quisqualate currents. Brain Res 1993; 608: 7-15.
33. Jackson MF, Joo DT, Al-Mahrouki AA, Orser BA, Macdonald JF: Desensitization of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors facilitates use-dependent inhibition by pentobarbital. Mol Pharmacol 2003; 64: 395-406.
34. Joo DT, Xiong Z, MacDonald JF, Jia Z, Roder J, Sonner J, Orser BA: Blockade of glutamate receptors and barbiturate anesthesia: increased sensitivity to pentobarbital-induced anesthesia despite reduced inhibition of AMPA receptors in GluR2 null mutant mice. Anesthesiology 1999; 91: 1329-1341.
35. Taverna FA, Cameron BR, Hampson DL, Wang LY, MacDonald JF: Sensitivity of AMPA receptors to pentobarbital. Eur J Pharmacol 1994; 267:R3-R5.
36. Yamakura T, Sakimura K, Mishina M, Shimoji K: The sensitivity of AMPA-selective glutamate receptor channels to pentobarbital is determined by a single amino acid residue of the alpha 2 subunit. FEBS Lett 1995; 374: 412-414.
37. Babaei A, Eslamai MH: Evaluation of therapeutic drug level monitoring of phenobarbital, phenytoin and carbamazepine in Iranian epileptic patients. Int J Clin Pharmacol Ther 2007; 45: 121-125.